|
1.
|
|
22 p, 2.3 MB |
ISOTOPE : ISOform-guided prediction of epiTOPEs in cancer
/
Trincado Alonso, Juan Luis, 1987- (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Reixachs Solé, Marina (EMBL Australia Partner Laboratory Network at the Australian National University) ;
Pérez Granado, Judith (Hospital del Mar (Barcelona, Catalunya)) ;
Fugmann, Tim (Philochem AG) ;
Sanz, Ferran (Hospital del Mar (Barcelona, Catalunya)) ;
Yokota, Jun (National Cancer Center Research Institute (NCCRI)) ;
Eyras, Eduardo (Institut Hospital del Mar d'Investigacions Mèdiques)
Immunotherapies provide effective treatments for previously untreatable tumors and identifying tumor-specific epitopes can help elucidate the molecular determinants of therapy response. Here, we describe a pipeline, ISOTOPE (ISOform-guided prediction of epiTOPEs In Cancer), for the comprehensive identification of tumor-specific splicing-derived epitopes. [...]
2021 -  10.1371/journal.pcbi.1009411
PLoS computational biology, Vol. 17 Núm. 9 (september 2021) , p. e1009411
|
|
|
2.
|
|
15 p, 1.4 MB |
Gene amplification-associated overexpression of the selenoprotein trna enzyme trit1 confers sensitivity to arsenic trioxide in small-cell lung cancer
/
Coll-Sanmartin, Laia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Davalos, Veronica (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Piñeyro, David (Centro de Investigación Biomédica en Red de Cáncer) ;
Rosselló-Tortella, Margalida (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bueno-Costa, Alberto (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Setien, Fernando (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Villanueva, Alberto (Grup de Quimioresistències i Factors Predictius, Subprograma Contra la Resistència Terapèutica del Càncer (ProCURE)) ;
Granada, Isabel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ruiz-Xiviller, Neus (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Kotter, Annika (Johannes Gutenberg-Universität Mainz) ;
Helm, Mark (Johannes Gutenberg-Universität Mainz) ;
Yokota, Jun (National Cancer Center Research Institute (Japò)) ;
Kawabata-Iwakawa, Reika (Gunma University Initiative for Advanced Research) ;
Kohno, Takashi (National Cancer Center (Japò)) ;
Esteller, M. (Universitat de Barcelona. Departament de Ciències Fisiològiques)
2021 - 10.3390/cancers13081869
Cancers, Vol. 13 Núm. 8 (february 2021) , p. 1869
|
|
|
3.
|
|
13 p, 5.3 MB |
BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC
/
Jauset González, Toni (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Massó Vallés, Daniel (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Martínez Martín, Sandra (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Beaulieu, Marie-Eve (Vall d'Hebron Institut d'Oncologia) ;
Foradada Felip, Laia (Vall d'Hebron Institut d'Oncologia) ;
Fiorentino, Francesco Paolo (Department of Biomedical Sciences, University of Sassari) ;
Yokota, Jun (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Haendler, Bernard (Drug Discovery, Bayer AG) ;
Siegel, Stephan (Drug Discovery, Bayer AG) ;
Whitfield, Jonathan R. (Vall d'Hebron Institut d'Oncologia) ;
Soucek, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Effectively treating KRAS-driven tumors remains an unsolved challenge. The inhibition of downstream signaling effectors is a way of overcoming the issue of direct targeting of mutant KRAS, which has shown limited efficacy so far. [...]
2018 - 10.18632/oncotarget.24648
Oncotarget, Vol. 9 (april 2018) , p. 18734-18746
|
|
|
4.
|
|
15 p, 7.1 MB |
Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation
/
Fiorentino, Francesco Paolo (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ;
Tokgün, Elvan (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ;
Solé-Sánchez, Sònia (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ;
Giampaolo, Sabrina (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ;
Tokgün, Onur (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ;
Jauset González, Toni (Vall d'Hebron Institut d'Oncologia) ;
Kohno, Takashi (National Cancer Center Research Institute (Tòquio, Japó)) ;
Perucho, Manuel (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ;
Soucek, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Yokota, Jun (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer)
Small cell lung cancer (SCLC) is the most aggressive type of lung cancer with high mortality. One of the MYC family genes, MYC, MYCL or MYCN, is amplified in ~20% of the SCLCs; therefore, MYC proteins are potential therapeutic targets in SCLC patients. [...]
2016 - 10.18632/oncotarget.8826
Oncotarget, Vol. 7, Num. 21 (May 2016) , p. 31014-31028
|
|
|
5.
|
|
7 p, 525.4 KB |
Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma
/
Shiraishi, Kouya (National Cancer Center Research Institute (Tòquio, Japó)) ;
Okada, Yukinori (Tokyo Medical and Dental University) ;
Takahashi, Atsushi (RIKEN Center for Integrative Medical Sciences (Yokohama, Japó)) ;
Kamatani, Yoichiro (RIKEN Center for Integrative Medical Sciences (Yokohama, Japó)) ;
Momozawa, Yukihide (RIKEN Center for Integrative Medical Sciences (Yokohama, Japó)) ;
Ashikawa, Kyota (RIKEN Center for Integrative Medical Sciences (Yokohama, Japó)) ;
Kunitoh, Hideo (Japanese Red Cross Medical Center (Tòquio, Japó)) ;
Matsumoto, Shingo (National Cancer Center Research Institute (Tòquio, Japó)) ;
Takano, Atsushi (The University of Tokyo) ;
Shimizu, Kimihiro (Gunma University Hospital (Maebashi, Japó)) ;
Goto, Akiteru (Akita University (Akita, Japó)) ;
Tsuta, Koji (National Cancer Center Hospital (Tòquio, Japó)) ;
Watanabe, Shun-ichi (National Cancer Center Hospital (Tòquio, Japó)) ;
Ohe, Yuichiro (National Cancer Center Hospital (Tòquio, Japó)) ;
Watanabe, Yukio (National Cancer Center Hospital (Tòquio, Japó)) ;
Goto, Yasushi (National Cancer Center Hospital (Tòquio, Japó)) ;
Nokihara, Hiroshi (National Cancer Center Hospital (Tòquio, Japó)) ;
Furuta, Koh (National Cancer Center Hospital (Tòquio, Japó)) ;
Yoshida, Akihiko (National Cancer Center Hospital (Tòquio, Japó)) ;
Goto, Koichi (National Cancer Center Hospital East (Chiba, Japó)) ;
Hishida, Tomoyuki (National Cancer Center Hospital East (Chiba, Japó)) ;
Tsuboi, Masahiro (National Cancer Center Hospital East (Chiba, Japó)) ;
Tsuchihara, Katsuya (National Cancer Center Research Institute (Tòquio, Japó)) ;
Miyagi, Yohei (Kanagawa Cancer Center Research Institute (Yokohama, Japó)) ;
Nakayama, Haruhiko (Kanagawa Cancer Center (Yokohama, Japó)) ;
Yokose, Tomoyuki (Kanagawa Cancer Center (Yokohama, Japó)) ;
Tanaka, Kazumi (Gunma University Hospital (Maebashi, Japó)) ;
Nagashima, Toshiteru (Gunma University Hospital (Maebashi, Japó)) ;
Ohtaki, Yoichi (Gunma University Hospital (Maebashi, Japó)) ;
Maeda, Daichi (Akita University (Akita, Japó)) ;
Imai, Kazuhiro (Akita University (Akita, Japó)) ;
Minamiya, Yoshihiro (Akita University (Akita, Japó)) ;
Sakamoto, Hiromi (National Cancer Center Research Institute (Tòquio, Japó)) ;
Saito, Akira (StaGen Co., Ltd. (Tòquio, Japó)) ;
Shimada, Yoko (National Cancer Center Research Institute (Tòquio, Japó)) ;
Sunami, Kuniko (National Cancer Center Research Institute (Tòquio, Japó)) ;
Saito, Motonobu (National Cancer Center Research Institute (Tòquio, Japó)) ;
Inazawa, Johji (Tokyo Medical and Dental University) ;
Nakamura, Yusuke (University of Chicago) ;
Yoshida, Teruhiko (National Cancer Center Research Institute (Tòquio, Japó)) ;
Yokota, Jun (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ;
Matsuda, Fumihiko (Kyoto University) ;
Matsuo, Keitaro (Aichi Cancer Center Research Institute (Nagoya, Japó)) ;
Daigo, Yataro (The University of Tokyo) ;
Kubo, Michiaki (RIKEN Center for Integrative Medical Sciences (Yokohama, Japó)) ;
Kohno, Takashi (National Cancer Center Research Institute (Tòquio, Japó))
Lung adenocarcinoma driven by somatic EGFR mutations is more prevalent in East Asians (30-50%) than in European/Americans (10-20%). Here we investigate genetic factors underlying the risk of this disease by conducting a genome-wide association study, followed by two validation studies, in 3,173 Japanese patients with EGFR mutation-positive lung adenocarcinoma and 15,158 controls. [...]
2016 - 10.1038/ncomms12451
Nature communications, Vol. 7 (August 2016) , art. 12451
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
